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Introduction 55 56
The Mycobacterium abscessus complex (M. abscessus) are rapidly growing nontuberculous 57 mycobacterium (NTM) of increasing clinical concern with a rising burden of associated 58 pulmonary disease (Prevots et al. 2010) . M. abscessus poses a significant problem, particularly 59 in patients with cystic fibrosis (CF), where infection is associated with a more rapid decline in 60 lung function and can be a barrier to transplantation (Esther et al. 2010) . Of particular concern 61 are the findings from recent work that have suggested person-to-person transmission of virulent 62 clones amongst the CF population within a healthcare setting (Bryant et al. 2013 (Bryant et al. , 2016 , 63 although not all studies have supported this (Harris et al. 2014; Tortoli et al. 2017) . 64
65
The taxonomy of M. abscessus is contentious. It is currently divided into three subspecies: M. 66 abscessus subspecies abscessus (Mabs), M. abscessus subspecies massiliense (Mmas), and 67 M. abscessus subspecies bolletii (Mbol) (Adekambi et al. 2017) . The organism has intrinsic 68 resistance to multiple antibiotics including β -lactams, rifampicin and aminoglycosides due to the 69 synergistic action of the cell envelope and genetic factors (Nessar et al. 2012) . Treatment 70 requires prolonged courses of multiple antibiotics, but outcomes are thought to vary across the 71 different subspecies. Mmas has been associated with clarithromycin susceptibility and 72 favourable treatment outcomes, whereas Mabs has been associated with inducible macrolide 73 resistance and poorer treatment outcomes (Koh et al. 2011) . 74 75 Whole genome sequencing has been implemented in stages across England since December 76 2016, replacing existing reference techniques for mycobacterial identification. As a 77 consequence, there is now the opportunity to explore the molecular determinants of drug 78 resistance for all clinical NTM isolates. Macrolides are important agents in the management of 79 NTM infection, The American Thoracic Society/Infectious Diseases Society of America and 80 British Thoracic Society (ATS/IDSA and BTS) guidelines recommend including a macrolide in 81 treatment regimens where samples are either susceptible, or demonstrate inducible resistance 82 (Haworth et al. 2017; Griffith et al. 2007 ).. They act by binding to the 50S ribosomal subunit and 83 resistance in mycobacteria primarily occurs through target site modification for example by erm 84 methylases and point mutations (Nash, Brown-Elliott, and Wallace 2009) .As there is a 85 particularly strong correlation between in vitro susceptibility and clinical response to macrolide 86 treatment of M. abscessus (Jeon et al. 2009; Choi et al. 2017) , we have undertaken a study to 87 assess the feasibility of predicting clarithromycin susceptibility from whole genome sequencing 88 We next sought all available clinical isolates (N = 180) which had undergone whole genome 106 sequencing by the Public Health England (PHE) laboratory in Birmingham (UK) as part of the 107 routine diagnostic workflow, and for which paired phenotypic data were also available. We 108 supplemented this with 23 isolates for which the same data was available from a WGS archive 109 at the University of Oxford. Isolates were collected between May 2014 and January 2017 and 110 no prior selection according to site of isolation nor whether confirmed M. abscessus complex 111 disease by guidelines was made. Clinical samples were cultured in BD BACTEC™ MGIT™ 112 liquid mycobacterial growth indicator tubes from which an aliquot was removed to be prepared 113 for WGS as previously described (Votintseva et al. 2015) . 114
115
Libraries for Illumina Miseq sequencing were prepared using the Illumina Nextera XT protocol 116 with manual library normalisation. Samples where batched 12 to 16 per flow cell and paired end 117 sequencing was performed with the MiSeq reagent kit V2. Bioinformatics was performed using 118 the PHE bioinformatics pipeline as previously described (Walker et al. 2015; Votintseva et al. 119 2015) . Briefly, reads were mapped to the Mabs reference genome (NC_010397.1) with Stampy 120 v1.22 and variants called using Samtools v0.1.18 (Only variants with >= 5 high-quality reads, 121 mean quality per base >= 25 and > 90% high-quality bases were retained as variants; 122 heterozygous variants with >10% minor variant were not retained). A self-self blast approach 123 was used to mask repetitive regions. Sub-species were identified by computing maximum 124 likelihood (ML) phylogenetic trees incorporating published representative isolates from each 125 subspecies. A whole genome SNP alignment was used as input to IQ-TREE OMP version 1.5.5 126 using a generalised time reversible model. The erm(41) and rplV genes were manually 127 inspected for insertions/deletions from aligned fasta files using Seaview version 4.6.2. All newly 128 sequenced data has been uploaded to NCBI under project accession number PRJNA420644. We used BioPython software to extract base calls from whole genome sequence FASTA files, 147 comparing these to a list of genomic loci which our literature search indicated were associated 148 with clarithromycin resistance (table 2) . We then predicted phenotypes using an hierarchical 149 algorithm ( Figure 2 ). A resistant phenotype was predicted where any mutations were present at 150 rrl positions 2270 or 2271 (E. coli numbering 2058/2059), or where the less well characterized 151 rrl_A2269G or rrl_A2293C or rrl_G2281A mutations were seen. In the absence of these 152 mutations, susceptibility was predicted where an isolate had a truncated erm(41) gene or a C 153 nucleotide at position 28 in erm(41). Inducible resistance was predicted where a wild type call 154 (T) was present at position 28 in erm41. However, if an erm41_C19T mutation was also 155 present, susceptibility was predicted instead of inducible resistance. In cases where there was a 156 null call at rrl 2270/2271, we subsequently attempted local assembly of the rrl gene using Ariba 157 (Hunt et al. 2017) , followed by comparison by alignment against the reference. Where this was 158 not possible due to low coverage in this region, no prediction was made. Statistics quoted were 159 calculated using R Studio v1. (41), associated with inducible resistance. 208
Mechanisms of resistance 210 211
The negative predictive value of a truncated erm(41) gene for clarithromycin susceptibility was 212 53% (21/39 -there was one Mmas isolate with a full length erm (41)). In 11/18 instances, 213 resistance in the presence of a truncated erm(41) could be explained by a mutation in position 214 2270 or 2271 in rrl. No coverage at all was seen at these positions for 4/18 isolates. No genomic 215 explanation could be identified for the remaining three discordant isolates (table 1) . 216 217 All isolates which had any mutation of positions 2269 , 2270 or 2271 (E. Coli numbering 2057 , 218 2058 , 2059 in rrl were resistant to clarithromycin (21/203 (10%)). Such a mutation was found in 219
3 Mbol, 11 Mmas and 7 Mabs isolates. We did not observe any isolates with an rrl mutation 220 which also harboured a T28C mutation in erm (41) . Where this occurred in isolates reported in 221 the literature, they were always resistant Rubio et al. 2015) . 222
223
Of 37 isolates with a T28C mutation in erm (41) We conducted a systematic review of drug resistance determining mutations for clarithromycin 246 in M. abscessus and used the results to make genotypic predictions. The sensitivity of this 247 approach was 95% (95% CI 89 -98%) and the positive predictive value 78% (95% CI 69 -248 85%). The prevalence of resistance amongst our collection of isolates was high compared to 249 that which has been reported elsewhere (Koh et al. 2011; Hatakeyama et al. 2017; Li et al. 250 2016; Cowman et al. 2016) . 251
252
These results show that for clarithromycin, drug resistance can be predicted from WGS data as 253 it has been previously through targeted PCR and line probe assays such as the Hain GenoType 254 NTM-DR. Assessment of the genotype of erm(41) with molecular diagnostics allows prediction 255 of its functional status which has been thought to correlate to treatment outcome (Haworth et al. 256 2017) . Similarly, as the absence of a functional erm(41) gene has been associated with good 257 therapeutic outcomes its molecular detection ought to be beneficial to patients (Koh et al. 2011), 258 although in our study this alone was not an adequate predictor of in vitro resistance. A 259 genotypic prediction of inducible resistance produced a variable phenotype in our study (27/101 260 sensitive) . Discriminating such isolates predicted to be inducibly resistant which are 261 unexpectedly sensitive after prolonged incubation with clarithromycin or show early time point 262 high level resistance may help to identify additional genotypic markers to better identify patients 263 more likely to benefit from the use of macrolides... 264
265
In addition to mutations identified in the literature search, we also managed to identify variants 266 that may plausibly be new resistance determining mutations. However, these will require 267 validation against an independent data set. Using routinely collected diagnostic data to improve 268 our understanding of the molecular determinants of drug resistance is a key advantage WGS 269 has over line-probe assays or PCR. The eight previously undescribed mutations we report in 270 this work could be of clinical importance because they all occur in samples which the existing 271 literature predicts to be inducibly resistant. As BTS guidelines recommend that patients with 272 such isolates should be given a macrolide, it is important to determine further whether these 273
SNPs are true resistance-determinants, and whether macrolide therapy should be avoided in 274 their presence. 275
276
Previous authors have suggested that it is clinically useful to discriminate between subspecies, 277 (Koh et al. 2011) as Mmas is typically associated with durable susceptibility to clarithromycin 278
and Mbol and Mabs with inducible resistance (unless the T28C mutation is present). We found 279 identifying sub-species alone to be an inadequate predictor of in vitro clarithromycin phenotype. 280
There were three Mmas isolates in our collection that were resistant to clarithromycin and had 281 no mutations known to be relevant. Mougari and colleagues found that in 39/40 Mmas selected 282 for clarithromycin resistance, this could be explained by an rrl mutation at positions 2270/2271 283 with a further sample containing an rplV insertion . All of our isolates 284 contained this 'insertion' (also present in the NC_010397.1 reference) which was associated with 285 susceptibility to clarithromycin except in the presence of a relevant rrl mutation. 286
287
In keeping with previous reports, we identified an isolate of Mmas with a full length erm(41) and 288 a thymine nucleotide at position 28 . This likely represents recombination 289 between the subspecies. A recent study showed the Hain GenoType NTM-DR line probe assay 290 incorrectly predicted subspecies in 8% of samples, presumably because it lacks the whole 291 genome resolution provided by sequencing and is vulnerable to between species recombination 292 . 293 294 Despite analysing all mutations occurring in erm(41) and rrl for the full collection of genomes, 295
we were unable to predict all clarithromycin resistance. This may be because there are other 296 genes implicated or due to unreliable DST results. Future work should aim to select discordant 297 genotypes and identify additional infrequently occurring genetic loci implicated in clarithromycin 298 resistance, for example by using genome wide association (GWAS) approaches. All of the new 299 clarithromycin resistance mutations we discovered occurred in isolates which we originally 300 predicted to be inducibly resistant. Although M. abscessus is primarily thought to be an 301 environmental organism, these patients may be colonised for long periods with subsequent 302 potential exposure to multiple courses of macrolides. An alternative hypothesis may therefore 303 be that some or all of these SNPs are compensatory mutations which act to reduce a fitness 304 cost of the expression of erm, which has been experimentally demonstrated in other bacteria 305 (Gupta et al. 2013 ). There were four SNPs which only occurred in resistant samples but were 306 always seen with a known drug resistance causing SNP, possibly also representing 307 compensatory mutations. 308
309 Key weaknesses of our study include that we were unable establish a temporal relationship 310 between antibiotic prescribing and inducible phenotypic resistance as we did not have the 311 relevant ethics approval to link to patient records. If for example, any SNPs on our list of novel 312 mutations were observed in isolates from patients who had never previously had macrolide 313 therapy, it would be much more likely that they were genuine resistance conferring rather than 314 compensatory mutations. In addition it is possible that some of the genomes were same patient 315
replicates over a number of months/years, although this may have also diversified the range of 316 mutations observed. We chose to include all available samples to maximise detection of low 317 frequency resistance determining SNPs meaning there was no validation set available. Our list 318 of novel resistance determining SNPs will therefore require validation on an independent 319 dataset before being applied to the clinical setting. We chose to target a select list of genes with 320 known SNPs identified in the literature search; other approaches such as GWAS will likely be 321 additive to the knowledge base we present here. not support the replacement of phenotypic tests at this point in time; as more paired 328 genome/DST data becomes available in the near future, and we learn more about the molecular 329 determinants of drug resistance, it is likely that sensitivity and specificity of WGS resistance 330 prediction will improve. Given that WGS data is already being produced in the UK for the 331 purposes of molecular epidemiology, it would now be possible to phase out existing molecular 332 tests and replicate their results in silico at no additional cost. 333 334 Transparency declaration 335 
